David Ruano-Gallego1, Miriam García-Villadangos1, Mercedes Moreno-Paz1, Javier Gómez-Elvira2, Marina Postigo1, María Simón-Sacristán3, Hugh T Reyburn4, Carlo Carolis5, Natalia Rodrigo5, Yaiza B Codeseira6, Paloma Rueda7, Sonia Zúñiga8, Luis Enjuanes8, Victor Parro1. 1. Department of Molecular Evolution, Centro de Astrobiología (INTA-CSIC), Carretera de Ajalvir km 4, Torrejón de Ardoz, Madrid, 28850, Spain. 2. Space Payload Department, Instituto Nacional de Técnica Aeroespacial (INTA), Carretera de Ajalvir km 4, Torrejón de Ardoz, Madrid, 28850, Spain. 3. Microbiology and Parasitology Unit, Hospital Central de la Defensa 'Gómez Ulla', Glorieta del Ejército 1, Madrid, 28050, Spain. 4. Department of Immunology and Oncology, Centro Nacional de Biotecnología (CNB-CSIC), C/ Darwin 3, Madrid, 28049, Spain. 5. CRG-Centre for Genomic Regulation, Dr. Aiguader 88, Barcelona, 08003, Spain. 6. CIMUS Biomedical Research Institute, University of Santiago de Compostela-IDIS, Avenida de Barcelona s/n, Santiago de Compostela, 15782, Spain. 7. Eurofins-INGENASA, Avenida Institución Libre de Enseñanza 41, Madrid, Spain. 8. Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB-CSIC), C/ Darwin 3, Madrid, 28049, Spain.
Abstract
The surge of SARS-CoV-2 has challenged health systems worldwide and efficient tests to detect viral particles, as well as antibodies generated against them, are needed. Specificity, sensitivity, promptness or scalability are the main parameters to estimate the final performance, but rarely all of them match in a single test. We have developed SCOVAM, a protein microarray with several viral antigens (spike, nucleocapsid, main protease Nsp5) as capturing probes in a fluorescence immunoassay for COVID-19 serological testing. SCOVAM depicts IgG and IgM antibody responses against each of these proteins of 22 individuals in a single microscope slide. It detects specific IgM (0.094 μg ml-1 ) and IgG (~0.017 μg ml-1 ) and is scalable and cost-effective. We validated SCOVAM by comparing with a widely used chemiluminescent commercial serological test (n = 742). SCOVAM showed twice the sensitivity and allowed following seroconversion in a single assay. By analysing the prevalence 4 months later in a subset of 76 positive sera, we still detected 93.42% of positives, almost doubling the detection of the commercial assay. The higher sensitivity of SCOVAM is especially relevant to screen sera for convalescent plasma-based treatments, high-throughput antibody response monitoring after vaccination or evaluation of vaccine efficiency.
The surge of SARS-CoV-2 has challenged health systems worldwide and efficient tests to detect viral particles, as well as antibodies generated agaiene">nst them, are needed. Specificity, sensitivity, promptene">ness or scalability are the maiene">n parameters to estimate the fiene">nal performance, but rarely all of them match iene">n a siene">ngle test. We have developed n class="Gene">SCOVAM, a protein microarray with several viral antigens (spike, nucleocapsid, main proteaseNsp5) as capturing probes in a fluorescence immunoassay for COVID-19serological testing. SCOVAM depicts IgG and IgM antibody responses against each of these proteins of 22 individuals in a single microscope slide. It detects specific IgM (0.094 μg ml-1 ) and IgG (~0.017 μg ml-1 ) and is scalable and cost-effective. We validated SCOVAM by comparing with a widely used chemiluminescent commercial serological test (n = 742). SCOVAM showed twice the sensitivity and allowed following seroconversion in a single assay. By analysing the prevalence 4 months later in a subset of 76 positive sera, we still detected 93.42% of positives, almost doubling the detection of the commercial assay. The higher sensitivity of SCOVAM is especially relevant to screen sera for convalescent plasma-based treatments, high-throughput antibody response monitoring after vaccination or evaluation of vaccine efficiency.
Authors: Alba Fresco-Taboada; Marga García-Durán; Cristina Aira; Lissett López; Patricia Sastre; Lia van der Hoek; Marit J van Gils; Philip J M Brouwer; Rogier W Sanders; Barbara Holzer; Irene Zimpernikc; Eduardo López-Collazo; Patricia Muñoz; Paloma Rueda; Carmen Vela Journal: Diagn Microbiol Infect Dis Date: 2022-01-26 Impact factor: 2.983
Authors: Rebeca M Torrente-Rodríguez; Ana Montero-Calle; Clara San Bartolomé; Olga Cano; Mónica Vázquez; María Iglesias-Caballero; Andrés Corral-Lugo; Michael J McConnell; Mariona Pascal; Vicente Mas; José M Pingarrón; Rodrigo Barderas; Susana Campuzano Journal: Angew Chem Int Ed Engl Date: 2022-05-24 Impact factor: 16.823
Authors: Rebeca M Torrente-Rodríguez; Ana Montero-Calle; Clara San Bartolomé; Olga Cano; Mónica Vázquez; María Iglesias-Caballero; Andrés Corral-Lugo; Michael J McConnell; Mariona Pascal; Vicente Mas; José M Pingarrón; Rodrigo Barderas; Susana Campuzano Journal: Angew Chem Weinheim Bergstr Ger Date: 2022-05-24